Incresync (Pioglitazone, Alogliptin)

Incresync is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion.

• Type 2 diabetes mellitus (monotherapy): lowers fasting plasma glucose and HbA1c levels.
• Type 2 diabetes mellitus (combination therapy): enhances overall glycaemic control when added to metformin or sulfonylureas.
• Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise interventions to maintain target glucose levels.

• Pioglitazone activates peroxisome proliferator‑activated receptor‑γ (PPAR‑γ), which modulates transcription of genes involved in glucose and lipid metabolism, thereby increasing peripheral insulin sensitivity. Alogliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing degradation of incretin hormones such as GLP‑1 and GIP, which prolongs glucose‑dependent insulin secretion and suppresses glucagon release. The combined action improves overall glycaemic control, resulting in lower blood glucose concentrations throughout the day.

Incresync may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects

• Edema: mild to moderate swelling of the lower extremities.
• Weight gain: gradual increase in body weight.
• Upper respiratory tract infection: symptoms such as cough and sore throat.
• Headache: mild to moderate intensity.
• Gastrointestinal discomfort: nausea or dyspepsia.

Serious or Rare Side Effects

• Congestive heart failure exacerbation: worsening of pre‑existing heart failure.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Pancreatitis: severe abdominal pain with elevated pancreatic enzymes.
• Bone fracture: increased risk of femoral fractures.
• Bladder cancer: rare but reported with long‑term pioglitazone use.
• Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.

When prescribing Incresync, clinicians should consider several safety measures.

• Monitor liver function: obtain baseline and periodic liver enzyme tests due to potential hepatotoxicity.
• Assess cardiac status: avoid use in patients with NYHA Class III/IV heart failure.
• Evaluate renal function: dose adjustment may be required in severe renal impairment.
• Observe weight changes: monitor for edema and unexplained weight gain.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk; consult a specialist.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Incresync can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Concomitant use with insulin or sulfonylureas: increased risk of hypoglycaemia.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): raise pioglitazone plasma concentrations.
• Rifampin or other CYP inducers: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate fluid retention and edema.
• ACE inhibitors or ARBs: monitor renal function and potassium levels when combined.
• NSAIDs: may affect renal clearance and increase risk of renal impairment.